ItHome Hypertension Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

Credits to the 👉🏾Source Link👉🏾 Olivia
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

(MENAFN – GetNews)

“Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market”

(Albany, US) DelveInsight has launched a new report on ” Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) – Market Insights, Epidemiology, and Market Forecast-2030

 

DelveInsight’s ” Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Insights, Epidemiology, and Market Forecast-2030″  report delivers an in-depth understanding of the Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) , historical and forecasted epidemiology as well as the Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some of the PH-ILD facts:

  • According to Somnath Pal et al., 12 million people in the United States are affected by interstitial lung disease.
  • According to the study conducted by Boris Duchemann et al., prevalence of sarcoidosis was found out to be 30.2 per 100,000, prevalence of connective tissue diseases associated ILDs was found out to be 12.1 per 100,000 and prevalence of idiopathic pulmonary fibrosis was found out to be 8.2 per 100,000.
  • As per the study published by Chang et al., 18.1% of the people with connective tissue diseases had both ILD and PH.
  • According to the study conducted by Shorr et al., 73.8% of the people are affected by Sarcoidosis had PH.

 

Request for free Sample Report :

 

Scope of PH-ILD Report:

  • The report covers the descriptive overview of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market

 

Some of PH-ILD Companies:

  • United Therapeutics
  • Reata Pharmaceuticals, Inc
  • Bayer
  • And Many Others

 

Request for free Sample Report :

 

Pulmonary hypertension , or PH, occurs when blood pressure within the lungs becomes abnormally elevated. It can be caused by a thickening of the pulmonary artery walls, heart failure, lung disease (such as interstitial lung disease), and clots within the lungs’ blood vessels. It is common for ILD patients to also develop pulmonary hypertension.

According to the American Lung Association, Pulmonary hypertension is a serious condition characterized by higher than normal pressure in the blood vessels between the lungs and the heart. In pulmonary hypertension, the pressure of blood in the lungs is increased either because the blood vessels are narrowed (a lung problem), or because the pressure in the heart chamber to where the blood is pumped (left atrium) is increased (heart problem), causing the backflow of the blood into the lungs.

Symptoms of PH are similar to those of ILD. Patients with PH often complain of shortness of breath with physical activity that gradually worsens over time.

 

Some of PH-ILD therapies :

  • Tyvaso Inhalation Solution (United Therapeutics)
  • Bardoxolone methyl (Reata Pharmaceuticals, Inc)
  • Riociguat (Bayer)
  • Tyvaso
  • And Many Others

 

Request for free Sample Report :

 

Table of Contents:

1. Key Insights

2. Executive Summary of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)

3. Competitive Intelligence Analysis for Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)

4. Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) : Market Overview at a Glance

5. Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) : Disease Background and Overview

6. Patient Journey

7. Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Treatment

11. Marketed Products

12. Emerging Therapies

13. Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) : Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Request for Detailed TOC : https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website:

MENAFN15022021003238003268ID1101605599


Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Source Link

related posts

Leave a Comment

This website uses cookies to improve your experience. We will assume you are ok with this, but you can opt-out if you wish. Accept Read More

%d bloggers like this: